Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells

Thumbnail Image
10826.pdf(429.71 KB)
Published version
O'Callagan, Grace
Kelly, Jacquie
Shanahan, Fergus
Houston, Aileen M.
Journal Title
Journal ISSN
Volume Title
Springer Nature
Published Version
Research Projects
Organizational Units
Journal Issue
Fas ligand (FasL/CD95L) is a member of the tumour necrosis factor superfamily that triggers apoptosis following crosslinking of the Fas receptor. Despite studies strongly implicating tumour-expressed FasL as a major inhibitor of the anti-tumour immune response, little is known about the mechanisms that regulate FasL expression in tumours. In this study, we show that the cyclooxygenase (COX) signalling pathway, and in particular prostaglandin E2 (PGE2), plays a role in the upregulation of FasL expression in colon cancer. Suppression of either COX-2 or COX-1 by RNA interference in HCA-7 and HT29 colon tumour cells reduced FasL expression at both the mRNA and protein level. Conversely, stimulation with PGE2 increased FasL expression and these cells showed increased cytotoxicity against Fas-sensitive Jurkat T cells. Prostaglandin E2-induced FasL expression was mediated by signalling via the EP1 receptor. Moreover, immunohistochemical analysis using serial sections of human colon adenocarcinomas revealed a strong positive correlation between COX-2 and FasL (r=0.722; P<0.0001) expression, and between EP1 receptor and FasL (r=0.740; P<0.0001) expression, in the tumour cells. Thus, these findings indicate that PGE2 positively regulates FasL expression in colon tumour cells, adding another pro-neoplastic activity to PGE2.
Fas ligand , Prostaglandin E2 , Regulation , Tumour immune evasion , Colorectal Cancer , Carcinoma , Induced apoptosis , Immune privilege , Subtype EP1 , Cyclooxygenase 2 , Counterattack
O'Callaghan, G., Kelly, J., Shanahan, F. and Houston, A. (2008) 'Prostaglandin E2 stimulates Fas ligand expression via the EP1 receptor in colon cancer cells', British Journal Of Cancer, 99, pp. 502-512. doi: 10.1038/sj.bjc.6604490